Table 4.

Clinicopathological Features and Methylation of SFRP2, TFPI2, NDRG4 and BMP

Clinicopathological feature	SFRP2		TFPI2		NDRG4		BMP3
	No. (%)	p-value	No. (%)	p-value	No. (%)	p-value	No. (%)	p-value
Total positive	27		28		26		14
Age, yr		0.681		0.578		0.077		0.225
≤60	17 (63.0)		17 (60.7)		16 (61.5)		11 (78.6)
>60	10 (37.0)		11 (39.3)		10 (38.5)		3 (21.4)
Sex		0.624		0.498		0.070		0.662
Male	19 (70.4)		19 (67.9)		18 (69.2)		8 (57.1)
Female	8 (29.6)		9 (32.1)		8 (30.8)		6 (32.9)
Smoking		0.490		0.902		0.811		0.468
Nonsmoker	19 (70.4)		22 (78.6)		19 (73.1)		11 (78.6)
Ex-smoker	5 (18.5)		4 (14.3)		4 (15.4)		2 (14.3)
Current smoker	3 (11.1)		2 (7.1)		3 (11.5)		1 (7.1)
Tumor depth		0.344		0.416		0.364		0.498
T1	2 (7.4)		2 (7.1)		1 (3.8)		0
T2	4 (14.8)		3 (10.7)		4 (15.4)		3 (21.4)
T3	17 (63.0)		19 (67.9)		17 (65.4)		10 (71.5)
T4	4 (14.8)		4 (14.3)		4 (15.4)		1 (7.1)
Nodal status		0.180		0.853		0.150		0.205
N0	14 (51.9)		13 (46.4)		11 (42.3)		9 (64.3)
N1	8 (29.6)		11 (39.3)		9 (34.6)		5 (35.7)
N2	5 (18.5)		4 (14.3)		6 (23.1)		0
Metastasis		0.109		0.382		0.979		0.839
M0	19 (70.4)		18 (64.3)		15 (57.7)		10 (71.4)
M1	8 (29.6)		10 (35.7)		11 (42.3)		4 (28.6)
TNM stage*		0.120		0.399		0.092		0.798
I	5 (18.5)		4 (14.3)		4 (15.4)		2 (14.2)
II	6 (22.3)		6 (21.4)		4 (15.4)		4 (28.6)
III	8 (29.6)		8 (28.6)		8 (30.8)		4 (28.6)
IV	8 (29.6)		10 (35.7)		10 (38.4)		4 (28.6)

SFRP2, secreted frizzled-related protein 2; TFPI2, tissue factor pathway inhibitor 2; NDRG4, N-Myc downstream-regulated gene 4; BMP3, bone morphogenic protein 3; T, tumor; N, node; M, metastasis.

^*Tumor stage was determined with the use of the American Joint Committee on Cancer (AJCC) staging system (2009).